Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
PLoS One ; 15(4): e0226661, 2020.
Article in English | MEDLINE | ID: mdl-32240171

ABSTRACT

CD47 is an immune checkpoint protein that downregulates both the innate and adaptive anti-tumor immune response via its counter receptor SIRPα. Biologics, including humanized CD47 monoclonal antibodies and decoy SIRPα receptors, that block the SIRPα-CD47 interaction, are currently being developed as cancer immunotherapy agents. However, adverse side effects and limited penetration of tumor tissue associated with their structure and large size may impede their clinical application. We recently developed a quantitative high throughput screening assay platform to identify small molecules that disrupt the binding of SIRPα and CD47 as an alternative approach to these protein-based therapeutics. Here, we report on the development and optimization of a cell-based binding assay to validate active small molecules from our biochemical screening effort. This assay has a low volume, high capacity homogenous format that relies on laser scanning cytometry (LSC) and associated techniques to enhance signal to noise measurement of cell surface binding. The LSC assay is specific, concentration dependent, and validated for the two major human SIRPα variants (V1 and V2), with results that parallel those of our biochemical data as well as published studies. We also utilized the LSC assay to confirm published studies showing that the inhibition of amino-terminal pyroglutamate formation on CD47 using the glutaminyl cyclase inhibitor SEN177 disrupts SIRPα binding. The SIRPα-CD47 interaction could be quantitatively measured in live and fixed tumor cells. Use of fixed cells reduces the burden of cell maintenance and provides stable cell standards to control for inter- and intra-assay variations. We also demonstrate the utility of the assay to characterize the activity of the first reported small molecule antagonists of the SIRPα-CD47 interaction. This assay will support the screening of thousands of compounds to identify or validate active small molecules as hits, develop structure activity relationships and assist in the optimization of hits to leads by a typical iterative medicinal chemistry campaign.


Subject(s)
Adaptive Immunity/drug effects , Antigens, Differentiation/genetics , CD47 Antigen/genetics , Neoplasms/drug therapy , Receptors, Immunologic/genetics , Small Molecule Libraries/pharmacology , Adaptive Immunity/genetics , Aminoacyltransferases/antagonists & inhibitors , Aminoacyltransferases/chemistry , Antigens, Differentiation/chemistry , CD47 Antigen/chemistry , Drug Development , Gene Expression Regulation, Neoplastic/drug effects , High-Throughput Screening Assays/methods , Humans , Immunotherapy/methods , Jurkat Cells , Laser Scanning Cytometry , Ligands , Medical Oncology/trends , Neoplasms/genetics , Neoplasms/immunology , Neoplasms/pathology , Phagocytosis/drug effects , Protein Interaction Maps/genetics , Receptors, Immunologic/chemistry , Small Molecule Libraries/chemistry
2.
PLoS One ; 14(7): e0218897, 2019.
Article in English | MEDLINE | ID: mdl-31276567

ABSTRACT

CD47 is an immune checkpoint molecule that downregulates key aspects of both the innate and adaptive anti-tumor immune response via its counter receptor SIRPα, and it is expressed at high levels in a wide variety of tumor types. This has led to the development of biologics that inhibit SIRPα engagement including humanized CD47 antibodies and a soluble SIRPα decoy receptor that are currently undergoing clinical trials. Unfortunately, toxicological issues, including anemia related to on-target mechanisms, are barriers to their clinical advancement. Another potential issue with large biologics that bind CD47 is perturbation of CD47 signaling through its high-affinity interaction with the matricellular protein thrombospondin-1 (TSP1). One approach to avoid these shortcomings is to identify and develop small molecule molecular probes and pretherapeutic agents that would (1) selectively target SIRPα or TSP1 interactions with CD47, (2) provide a route to optimize pharmacokinetics, reduce on-target toxicity and maximize tissue penetration, and (3) allow more flexible routes of administration. As the first step toward this goal, we report the development of an automated quantitative high-throughput screening (qHTS) assay platform capable of screening large diverse drug-like chemical libraries to discover novel small molecules that inhibit CD47-SIRPα interaction. Using time-resolved Förster resonance energy transfer (TR-FRET) and bead-based luminescent oxygen channeling assay formats (AlphaScreen), we developed biochemical assays, optimized their performance, and individually tested them in small-molecule library screening. Based on performance and low false positive rate, the LANCE TR-FRET assay was employed in a ~90,000 compound library qHTS, while the AlphaScreen oxygen channeling assay served as a cross-validation orthogonal assay for follow-up characterization. With this multi-assay strategy, we successfully eliminated compounds that interfered with the assays and identified five compounds that inhibit the CD47-SIRPα interaction; these compounds will be further characterized and later disclosed. Importantly, our results validate the large library qHTS for antagonists of CD47-SIRPα interaction and suggest broad applicability of this approach to screen chemical libraries for other protein-protein interaction modulators.


Subject(s)
Antibodies, Monoclonal, Humanized/pharmacology , Antigens, Differentiation/metabolism , CD47 Antigen/metabolism , Drug Discovery/methods , High-Throughput Screening Assays/methods , Receptors, Immunologic/metabolism , Small Molecule Libraries/pharmacology , Animals , Antigens, Differentiation/chemistry , Biotin/chemistry , Biotin/metabolism , CD47 Antigen/chemistry , CD47 Antigen/immunology , Humans , Models, Molecular , Protein Binding/drug effects , Protein Domains , Receptors, Immunologic/chemistry , Reproducibility of Results , Signal Transduction/drug effects
SELECTION OF CITATIONS
SEARCH DETAIL
...